City University of New York (CUNY)

CUNY Academic Works
Publications and Research

Hunter College

2007

Medical Treatment and Weight Gain
Eileen McGinn
CUNY Hunter College

How does access to this work benefit you? Let us know!
More information about this work at: https://academicworks.cuny.edu/hc_pubs/145
Discover additional works at: https://academicworks.cuny.edu
This work is made publicly available by the City University of New York (CUNY).
Contact: AcademicWorks@cuny.edu

VOLUME 4: NO. 3

JULY 2007
LETTER TO THE EDITOR

Medical Treatment and Weight Gain

Suggested citation for this article: McGinn E. Medical treatment and weight gain [letter to the editor]. Prev Chronic
Dis [serial online] 2007 Jul [date cited]. Available from:
http://www.cdc.gov/pcd/issues/2007/jul/07_0081.htm.

To the Editor:
“Addressing the Obesity Epidemic: A Genomics
Perspective” in your April 2007 (1) issue speaks of
the importance of considering all aspects of obesity.
However, one aspect overlooked in the article is weight
gain associated with medical treatment. Many classes
of drugs are associated with weight gain that leads to
overweight or obesity; these include atypical antipsychotic drugs, lithium, some antidepressant drugs, some
antiepileptic drugs, and some steroids. Other drugs are
associated with fat redistribution (e.g., some drugs for
HIV/AIDS).
In addition to increasing weight, atypical antipsychotic
drugs increase risk for hyperglycemia (as noted in a blackbox label required by the Food and Drug Administration
[FDA]), and they are associated with lipid dysregulation (2). Atypical antipsychotic drugs induce excitation
and hypomania or mania, adverse effects never reported
for the older versions of typical antipsychotic drugs
(3). Some atypical antipsychotic drugs are also noncardiac
QTc-interval–prolonging drugs and are associated with
increased sudden cardiac death (4).   
Atypical antipsychotic drugs are widely used offlabel. The FDA issued a Public Health Advisory warning of a 60% to 70% increased risk for mortality among
elderly people with dementia being treated with atypical
antipsychotic medications (5). From 1993 through 2002,
prescriptions for atypical antipsychotic drugs for Ameri-

can children increased 500% (all off-label); 85% of those
prescriptions were for nonpsychotic conditions (6). The
public health implications of wide off-label use of this class
of drugs merits more study.
Eileen McGinn, MPH
Student
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